Oncology Institute Earnings Call Highlights Growth Pivot

Oncology Institute, Inc. ((TOI)) has held its Q1 earnings call. Read on for the main highlights of the call.

Oncology Institute, Inc.’s latest earnings call struck an overall upbeat tone, with management highlighting strong revenue growth, scaling specialty pharmacy operations and expanding value-based contracts. While acknowledging pressures on margins, fee-for-service revenues and refinancing risk, executives emphasized improving operating leverage, better cash flow trajectory and clear progress toward sustainable profitability.

Strong Top-Line Growth

Oncology Institute reported first-quarter 2026 revenue of $147.4 million, up 41.2% year over year, fueled by the expansion of capitated arrangements and higher specialty pharmacy volume. This growth underscores the company’s ability to win new contracts and deepen relationships in value-based oncology, positioning the business for greater scale in its core markets.

Robust Specialty Pharmacy Performance

Specialty pharmacy remained the primary growth engine, delivering $87.5 million of revenue, or 59.4% of the total, up 77.6% from a year ago as prescription fills surged about 103%. Pharmacy gross profit reached $16.8 million with a 19.2% margin that was essentially flat, suggesting the pharmacy platform is scaling efficiently while maintaining stable unit economics.

Capitation Momentum and Shift to Value-Based Care

Capitated revenue climbed 54% year over year to $26.9 million and now accounts for roughly 45.6% of patient services revenue, versus about 33% previously. This growing mix of value-based contracts signals that payers are increasingly willing to delegate risk to Oncology Institute, potentially unlocking more predictable revenue streams and margin upside over time.

Improved Profitability Trends and Cash Flow Outlook

Profitability metrics continued to trend in the right direction as adjusted EBITDA loss narrowed to $2.4 million from $5.1 million a year earlier, while operating cash flow improved to a $2.3 million outflow from $5.0 million. Management reaffirmed full-year adjusted EBITDA guidance of $0 to $9 million and notably lifted free cash flow expectations to a positive $5 million to $15 million, reinforcing confidence in the business model.

Florida Market Achievement

The Florida market emerged as a standout, turning profitable on a four-wall EBITDA basis and delivering a medical loss ratio near or slightly better than the 85% target for the 2025 delegated cohort. Building on this success, the company plans to expand to around 200,000 Medicare Advantage lives under delegated capitation across 25 counties by the third quarter, underscoring Florida’s role as a proving ground for its model.

Operating Leverage and SG&A Improvement

General and administrative expenses totaled $28.2 million, up in absolute terms but down to 19.1% of revenue from 24.3% a year ago, a roughly 520-basis-point improvement. This drop as a share of revenue reflects growing operating leverage as the company scales its platform, suggesting that incremental growth should increasingly flow through to the bottom line.

Technology and Cost-Savings Initiatives

Management highlighted AI-enabled efforts in revenue cycle, prior authorizations and call center operations that are on track to deliver about $2 million of operating expense savings in 2026. A proprietary provider portal, slated for launch in the third quarter, is expected to enhance treatment pathway adherence, utilization management and ancillary revenue capture, offering incremental efficiency and margin benefits.

Regulatory and Program Recognition

Oncology Institute noted that it saved nearly $2 million in Medicare spending under a recent period of a federal oncology model, showcasing the clinical and economic value of its integrated care approach. Such results help validate its value-based strategy and could support future discussions with payers and regulators seeking both cost control and quality outcomes.

Fee-for-Service Revenue Decline

Not all trends were favorable, as fee-for-service revenue fell about 10% year over year to $32.2 million despite higher patient visit volumes, reflecting a deliberate mix shift and tighter drug management. The company also booked conservative reserves against collections and faced modest pricing pressure in the IV drug channel, underscoring near-term headwinds in traditional volume-based revenue streams.

Patient Services Margin Compression

Patient services gross margin slipped to 9.7% from 11.3% a year earlier, a decline of roughly 163 basis points driven by ramping delegated contracts and conservative treatment of fee-for-service receivables. Management framed this as a temporary trade-off as new risk-bearing arrangements scale, with expectations that margins improve as cohorts mature and operational efficiencies take hold.

Overall Gross Margin Slightly Lower

Company-wide gross margin edged down to 15.8% from 16.5%, pressured by a greater mix of lower-margin delegated business and the absence of a nonrecurring rebate that benefited the prior year. While the shift is modest, investors will be watching how the company balances volume growth and value-based expansion with the need to stabilize and eventually expand gross profitability.

Q1 Seasonality and Ongoing Loss

Management reminded investors that the first quarter is typically seasonally soft due to deductible resets and annual drug cost increases, which weighed on results again this year. The company still reported a negative adjusted EBITDA of $2.4 million and negative operating cash flow, though both metrics improved, indicating that structural improvements are starting to offset seasonal pressure.

Pressure on Average Revenue per Pharmacy Fill

Average revenue per pharmacy fill fell about 12% year over year as the mix of drugs and payers evolved, partly offset by the sharp rise in fill volumes. Management cited a changing pricing environment as various policy changes phase in, highlighting that volume growth and cost management will be key to preserving pharmacy profitability in the current environment.

Leverage and Refinancing Risk

Liquidity remains adequate but not limitless, with cash and equivalents dipping to $30.3 million from $33.6 million at year-end and $85.9 million of senior secured convertible notes outstanding. Management disclosed that it is in late-stage discussions to refinance these obligations before their 2027 maturity, introducing some execution risk that investors will closely track alongside operating progress.

Guidance and Forward Outlook

Looking ahead, Oncology Institute reaffirmed its 2026 revenue outlook of $630 million to $650 million, including roughly $150 million from capitated contracts, with gross profit of $97 million to $107 million and adjusted EBITDA between break-even and $9 million. The company also guided to modestly negative to breakeven adjusted EBITDA in the second quarter, expects free cash flow of $5 million to $15 million for the year, plans to grow delegated Medicare Advantage lives to about 200,000 by midyear and reiterated expected cost savings from AI initiatives.

On balance, the earnings call painted a picture of a company in transition but gaining traction, with robust growth in specialty pharmacy and capitation outpacing manageable margin and financing headwinds. Investors will want to see continued progress toward sustained profitability, execution on delegated contracts and clarity around refinancing, but the upgraded cash flow outlook suggests the strategy is beginning to pay off.